Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)

The summary for the Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed): The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD) Areas of interest include but are not limited to: 1) Development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology 2) Development of assays to assess the effects of compounds on multiple targets or functions
Federal Grant Title: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education, Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-25-054
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Information not provided
Current Application Deadline: July 25th, 2024
Original Application Deadline: July 25th, 2024
Posted Date: January 29th, 2024
Creation Date: January 29th, 2024
Archive Date: August 30th, 2024
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: January 29th, 2024
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-054.html
Grant Announcement Contact
NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants
Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...
Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com